We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > idiopathic pulmonary fibrosis

News List

Cipla launches Nintib (Nintedanib) to treat Idiopathic Pulmonary Fibrosis expresspharma
October 22, 2020
Cipla has launched generic Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Available as 100 mg and 150 mg capsules, it will be marketed under the brand name Nintib.
Boehringer Ingelheim files for regulatory approval of nintedanib pharmaceutical-technology
March 20, 2019
Boehringer Ingelheim has filed regulatory submissions with the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD).
Aptuit and Chiesi initiate Integrated Discovery Project to identify novel compounds to treat Idiopat pharmaasia
January 18, 2017
The agreement will integrate early discovery capabilities to identify promising compounds for further pre-clinical development.